Answers are grounded in this paper and cite their sources.
Parkinson's disease (PD) is associated with sleep and motor function impairment, even in the early stages. Here, we investigated whether passive wearable-based sleep and activity tracking can detect PD and its associated pathological hallmarks, dopaminergic deficit and α-synuclein pathology. Sleep and activity metrics (SAM) were derived from free-living wrist accelerometry data of a U.S. cohort and used to train a machine learning model (SAM-PD) to distinguish persons with PD (n = 133) from healthy controls (n = 26). The model achieved an AUROC of 0.93 and an AUPRC of 0.98, demonstrated excellent test-retest reliability, and generalized without retraining to an independent European cohort (n = 40; 50% PwPD) monitored with a different device (AUROC, 0.95; AUPRC, 0.95). REM sleep duration, walking cadence, and low-level acceleration features were most predictive. Applied to a U.S. at-risk cohort, SAM-PD performed comparably to the resource-intensive Movement Disorder Society (MDS) prodromal PD risk score in detecting dopaminergic deficit (AUROC, 0.86 vs. 0.80; AUPRC, 0.45 vs. 0.46; n = 121; 12.4% prevalence) and α-synuclein pathology (AUROC, 0.76 for both; AUPRC 0.50 vs. 0.42; n = 114; 16.7% prevalence). A combination with the MDS score modestly improved detection. Findings support further evaluation of wearable monitoring for PD screening and biomarker enrichment in larger populations.
No takes yet. Share an insight, caveat, or question.
Moustaklis et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: